Jaguar Animal Health Announces Reverse Stock Split

Jaguar Animal Health ( (JAGX) ) has provided an update.

Jaguar Health, Inc. announced a reverse stock split of its common stock at a 1-for-25 ratio, effective March 24, 2025, to comply with Nasdaq listing standards and attract institutional investors. The reverse stock split will reduce the number of shares and increase the share price, with no fractional shares issued; stockholders will receive cash for any fractional shares. The company’s stock will continue trading on Nasdaq under the symbol ‘JAGX’ with a new CUSIP number.

More about Jaguar Animal Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines derived from plants from rainforest areas for people and animals with gastrointestinal distress. Its subsidiary, Napo Pharmaceuticals, develops and commercializes human prescription pharmaceuticals for managing neglected gastrointestinal symptoms, and its product crofelemer is FDA-approved for noninfectious diarrhea in adults with HIV/AIDS. Napo Therapeutics, based in Milan, Italy, aims to expand crofelemer access in Europe for orphan and rare diseases. Magdalena Biosciences, a joint venture with Filament Health Corp., focuses on developing plant-derived medicines for mental health indications.

YTD Price Performance: -56.97%

Average Trading Volume: 405,121

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $7.3M

Find detailed analytics on JAGX stock on TipRanks’ Stock Analysis page.